Trump's FDA: A Friendlier Biotech Sheriff

It is hard to believe we are coming up on the six-month mark since Donald Trump was sworn into office. While considerable headway has been made rolling back myriad regulations, the president's agenda remains bogged down in Congress. Repeal and replacement of the Affordable Care Act is looking less likely thanks to Republican infighting and a united opposition party. Prospects for significant tax reform and a large infrastructure bill also have dimmed.

The administration has less staff in place at this point than any in memory thanks to Democratic resistance as well as its own foibles. However, one place that has had effective leadership put in place is at the Food and Drug Administration (FDA), and it is this new FDA leadership that will have consequences for the pharma and biotech industries....435 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.

Read the full story and get access to the Real Money Pro trading floor.

There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.

Already a Subscriber? Please login.

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.